Subsequently, we investigated the sensitivity of AML cells to the MYC inhibitor 10058F4 and inhibitors targeting three key lipogenesis-related genes: Orlistat (targeting FASN), Fatostatin (targeting SREBF1), and A939572 (targeting SCD) [33–36]. This evidence concerns the gene FASN and acute myeloid leukemia.